Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.4.2343

Effects of Celecoxib on Cycle Kinetics of Gastric Cancer Cells and Protein Expression of Cytochrome C and Caspase-9  

Wang, Yu-Jie (Department of Gastroenterology, Zhengzhou People's Hospital Affiliated to Southern Medical University)
Niu, Xiao-Ping (Department of Digestion Medicine, Yijishan Hospital of Wannan Medicine College)
Yang, Li (Department of Gastroenterology, Zhengzhou People's Hospital Affiliated to Southern Medical University)
Han, Zhen (Department of Digestion Medicine, Yijishan Hospital of Wannan Medicine College)
Ma, Ying-Jie (Department of Gastroenterology, Zhengzhou People's Hospital Affiliated to Southern Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.4, 2013 , pp. 2343-2347 More about this Journal
Abstract
Objective: This investigation aimed to determine effects of celecoxib on the cell cycle kinetics of the gastric cancer cell line MGC803 and the mechanisms involved by assessing expression of cytochrome C and caspase-9 at the protein level. Methods: Cell proliferation of MGC803 was determined by MTT assay after treatment with celecoxib. Apoptosis was assessed using fluorescence staining and cell cycle kinetics by flow cytometry. Western blotting was used to detect the expression of caspase-9 protein and of cytochrome C protein in cell cytosol and mitochondria. Results: Celecoxib was able to restrain proliferation and induce apoptosis in a dose- and time-dependent manner, inducing G0/G1 cell cycle arrest, release of cytochrome C into the cytosol, and cleavage of pro-caspase-9 into its active form. Conclusion: Celecoxib can induce apoptosis in MGC803 cells through a mechanism involving cell cycle arrest, mitochondrial cytochrome C release and caspase activation.
Keywords
Celecoxib; MGC803; cell cycle; cytochrome C; caspase-9; apoptosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ogunwobi OO, Liu C (2011). Hepatocyte growth factor upregulation promotes carcinogenesis and epithelialmesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis, 28, 721-31.   DOI
2 Ohno Y, Ohno S, Suzuki N, et al (2005). Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinoma. Int J Cancer, 114, 696-701.   DOI   ScienceOn
3 Park SW, Kim HS, Hah JW, et al (2010). Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines. Anticancer Drugs, 21, 823-30.   DOI   ScienceOn
4 Pietenpol JA, Stewart ZA (2002). Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology, 181-182, 475-81.   DOI   ScienceOn
5 Smith WL, DeWitt DL, Garavito RM (2000). Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem, 69, 145-82.   DOI   ScienceOn
6 Sobolewski C, Cerella C, Dicato M, Diederich M (2011). Cox-2 inhibitors induce early c-Myc downregulation and lead to expression of differentiation markers in leukemia cells. Cell Cycle, 10, 2978-93.   DOI
7 Thiel A, Mrena J, Ristimaki A (2011). Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev, 30, 387-95.   DOI   ScienceOn
8 Wang GY, Zhang JW, Lu QH, Xu RZ, Dong QH (2007). Berbamine induces apoptosis in human hepatoma cell line SMMC7721 by loss in mitochondrial transmembrane potential and caspase activation. J Zhejiang Univ Sci B, 8, 248-55.   DOI   ScienceOn
9 Wu K, Nie Y, Guo C, et al (2009). Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol, 24, 37-41.   DOI   ScienceOn
10 Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS (2008). Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer, 122, 2115-24.   DOI   ScienceOn
11 Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T (2004). Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation, dependent on the cytochrome c/caspase-9 apoptosome. J Asian Nat Prod Res, 6, 127-38.   DOI   ScienceOn
12 Arber N (2008). Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol Biomarkers Prev, 17, 1852-7.   DOI   ScienceOn
13 Barr H (2011). Gastrointestinal cancer: current screening strategies. Recent Results Cancer Res, 185, 149-57.   DOI
14 Bazuro GE, Torino F, Gasparini G, Capurso L (2008). Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all? Minerva Gastroenterol Dietol, 54, 429-44.
15 Calviello G, Di Nicuolo F, Piccioni E, et al (2003). gamma-Tocopheryl quinone induces apoptosis in cancer cells via caspase-9 activation and cytochrome c release. Carcinogenesis, 24, 427-33.   DOI   ScienceOn
16 Chakraborti AK, Garg SK, Kumar R, Motiwala HF, Jadhavar PS (2010). Progress in COX-2 inhibitors: a journey so far. Curr Med Chem, 17, 1563-93.   DOI   ScienceOn
17 Chen WT, Hung WC, Kang WY, et al (2009). Overexpression of cyclooxygenase-2 in urothelial carcinoma in conjunction with tumor-associated-macrophage infiltration, hypoxiainducible factor-1alpha expression, and tumor angiogenesis. APMIS, 117, 176-84.   DOI   ScienceOn
18 Clemett D, Goa KL (2000). Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs, 59, 957-80.   DOI   ScienceOn
19 Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7.   DOI   ScienceOn
20 Entezari Heravi R, Hadizadeh F, Sankian M, et al (2011). Novel selective Cox-2 inhibitors induce apoptosis in Caco-2 colorectal carcinoma cell line. Eur J Pharm Sci, 44, 479-86.   DOI   ScienceOn
21 Fischer SM, Hawk ET, Lubet RA (2011). Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res, 4, 1728-35.   DOI   ScienceOn
22 Fisher JC, Gander JW, Haley MJ, et al (2011). Inhibition of cyclooxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor. Vasc Cell, 3, 22.   DOI   ScienceOn
23 Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K (2007). Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J Gastrointest Cancer, 38, 78-82.   DOI   ScienceOn
24 Ghosh N, Chaki R, Mandal V, Mandal SC (2010). COX-2 as a target for cancer chemotherapy. Pharmacol Rep, 62, 233-44.   DOI
25 Gu Q, Wang JD, Xia HH, et al (2005). Activation of the caspase-8/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer. Carcinogenesis, 26, 541-6.
26 Hsu YL, Kuo YC, Kuo PL, et al (2005). Apoptotic effects of extract from Antrodia camphorata fruiting bodies in human hepatocellular carcinoma cell lines. Cancer Lett, 221, 77-89.   DOI   ScienceOn
27 Khan Z, Khan N, Tiwari RP, et al (2011). Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets, 12, 1082-93.   DOI   ScienceOn
28 Lai MY, Huang JA, Liang ZH, et al (2004). Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res, 10, 8465-71.   DOI   ScienceOn
29 Li S, Tong Q, Zhang W, et al (2008). Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells. Cancer Invest, 26, 333-7.   DOI   ScienceOn
30 Liu H, Xiao J, Yang Y, et al (2011). COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer. Microvasc Res, 82, 131-40.   DOI   ScienceOn
31 Liou JP, Hsu KS, Kuo CC, Chang CY, Chang JY (2007). A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2, 3-dihydro-1H-indol-7-yl] -isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. J Pharmacol Exp Ther, 323, 398-405.   DOI   ScienceOn
32 Matthias C, Schuster MT, Zieger S, Harreus U (2006). COX-2 inhibitors celecoxib and rofecoxib prevent oxidative DNA fragmentation. Anticancer Res, 26, 2003-7.
33 Mehar A, Macanas-Pirard P, Mizokami A, et al (2008). The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents. J Pharmacol Exp Ther, 324, 1181-7.